{"id":86425,"date":"2026-05-13T12:47:37","date_gmt":"2026-05-13T07:17:37","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=86425"},"modified":"2026-05-13T12:47:39","modified_gmt":"2026-05-13T07:17:39","slug":"bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/","title":{"rendered":"Bliss GVS Pharma Q4 FY26 Results: Board Approves FY26 Results Recommends 100 Percent Dividend AGM July 15 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/blissgvs\/bliss-gvs-pharma-ltd-share-price-today\">Bliss GVS Pharma<\/a> Q4 FY26 results were approved by the board on 12 May 2026, with the company recommending a 100 percent final dividend (Re 1 per equity share of face value Re 1 each) for FY26, subject to shareholder approval at the 41st Annual General Meeting scheduled for July 15, 2026. The <strong>Bliss GVS Pharma Q4 FY26<\/strong> board meeting also confirmed the company&#8217;s audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. Bliss GVS Pharma is one of India&#8217;s largest manufacturers of suppositories and pessaries, with a significant global export footprint in Africa, Latin America, and Southeast Asia. For the trailing twelve months, the company reported revenue of approximately Rs 868 crore and profit of approximately Rs 114 crore.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#Bliss_GVS_Pharma_Q4_FY26_Key_Financial_Highlights\" title=\"Bliss GVS Pharma Q4 FY26 Key Financial Highlights\">Bliss GVS Pharma Q4 FY26 Key Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#Bliss_GVS_Pharma_Q4_FY26_Business_Overview_and_Performance\" title=\"Bliss GVS Pharma Q4 FY26 Business Overview and Performance\">Bliss GVS Pharma Q4 FY26 Business Overview and Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#Bliss_GVS_Pharma_FY27_Outlook\" title=\"Bliss GVS Pharma FY27 Outlook\">Bliss GVS Pharma FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#Frequently_Asked_Questions_on_Bliss_GVS_Pharma_Q4_FY26_Results\" title=\"Frequently Asked Questions on Bliss GVS Pharma Q4 FY26 Results\">Frequently Asked Questions on Bliss GVS Pharma Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#What_dividend_did_Bliss_GVS_Pharma_recommend_for_FY26\" title=\"What dividend did Bliss GVS Pharma recommend for FY26?\">What dividend did Bliss GVS Pharma recommend for FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#When_did_Bliss_GVS_Pharma_announce_Q4_FY26_results\" title=\"When did Bliss GVS Pharma announce Q4 FY26 results?\">When did Bliss GVS Pharma announce Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#What_is_Bliss_GVS_Pharmas_business\" title=\"What is Bliss GVS Pharma&#8217;s business?\">What is Bliss GVS Pharma&#8217;s business?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-q4-fy26-results-dividend-fy26-revenue-rs-868-crore\/#Where_can_I_track_Bliss_GVS_Pharma_Q4_FY26_live_data\" title=\"Where can I track Bliss GVS Pharma Q4 FY26 live data?\">Where can I track Bliss GVS Pharma Q4 FY26 live data?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Q4_FY26_Key_Financial_Highlights\"><\/span><strong>Bliss GVS Pharma Q4 FY26 Key Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th><strong>Parameter<\/strong><\/th>\n<th><strong>FY26 (TTM)<\/strong><\/th>\n<th><strong>Reference<\/strong><\/th>\n<\/tr>\n<tr>\n<td><strong>Revenue (Trailing 12 Months)<\/strong><\/td>\n<td>Approx. Rs 868 crore<\/td>\n<td>FY25 reference<\/td>\n<\/tr>\n<tr>\n<td><strong>Net Profit (TTM)<\/strong><\/td>\n<td>Approx. Rs 114 crore<\/td>\n<td>FY25 reference<\/td>\n<\/tr>\n<tr>\n<td><strong>Q3 FY26 PAT<\/strong><\/td>\n<td>Rs 24.78 crore<\/td>\n<td>Sequential base<\/td>\n<\/tr>\n<tr>\n<td><strong>Dividend<\/strong><\/td>\n<td>100% (Re 1 per share)<\/td>\n<td>41st AGM: July 15, 2026<\/td>\n<\/tr>\n<tr>\n<td><strong>Market Cap<\/strong><\/td>\n<td>Approx. Rs 2,883 crore<\/td>\n<td>As of May 12, 2026<\/td>\n<\/tr>\n<tr>\n<td><strong>NSE Ticker<\/strong><\/td>\n<td>BLISSGVS<\/td>\n<td>Sector: Specialty Pharmaceuticals<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/univest.in\/screeners\">Screen the best stocks on the Univest Screener.<\/a><\/p>\n<p>Investors tracking <strong>SKF India Industrial Q4 FY26 results<\/strong> can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Q4_FY26_Business_Overview_and_Performance\"><\/span><strong>Bliss GVS Pharma Q4 FY26 Business Overview and Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Bliss GVS Pharma Q4 FY26<\/strong> board meeting on May 12, 2026, approved the audited financial results and recommended a 100 percent final dividend, reflecting the company&#8217;s stable cash flow generation and shareholder return focus. Bliss GVS Pharma is internationally known as one of the largest manufacturers of suppositories and pessaries, serving healthcare markets across Africa, Latin America, Southeast Asia, and other emerging markets. The company&#8217;s business model is built on regulated market exports with long-term supply relationships with global pharmaceutical companies and healthcare agencies.<\/p>\n<p>The company has demonstrated resilience through its export-focused pharmaceutical manufacturing model. Q3 FY26 PAT was Rs 24.78 crore on revenue of Rs 218.25 crore. The company has also recently established a wholly-owned subsidiary in the Democratic Republic of Congo (DRC), expanding its footprint in Africa. Bliss GVS Pharma has gained ICRA&#8217;s A- (Stable) credit rating for its facilities, reinforcing its financial credibility. The <strong>Bliss GVS Pharma Q4 FY26<\/strong> results mark the completion of a year in which the company maintained its export-led growth trajectory in specialty pharmaceutical dosage forms.<\/p>\n<p>The board of Bliss GVS Pharma recommended a 100 percent final dividend (Re 1 per equity share) for FY26, subject to shareholder approval at the 41st Annual General Meeting on July 15, 2026.<\/p>\n<p>Investors tracking <strong>SKF India Industrial Q4 FY26 results<\/strong> can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_FY27_Outlook\"><\/span><strong>Bliss GVS Pharma FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Post <strong>Bliss GVS Pharma Q4 FY26 results<\/strong>, the FY27 outlook will be shaped by new market expansion in the DRC and other African markets, renewal and growth of existing long-term supply contracts, and the company&#8217;s ability to scale up new dosage form capabilities. The specialised nature of Bliss GVS Pharma&#8217;s products (suppositories, pessaries, and other alternative dosage forms) provides a competitive moat with limited domestic competition, supporting sustained export-led revenue growth.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Bliss_GVS_Pharma_Q4_FY26_Results\"><\/span><strong>Frequently Asked Questions on Bliss GVS Pharma Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_dividend_did_Bliss_GVS_Pharma_recommend_for_FY26\"><\/span><strong>What dividend did Bliss GVS Pharma recommend for FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bliss GVS Pharma recommended a 100 percent final dividend (Re 1 per equity share of face value Re 1 each) for FY26, subject to approval at the 41st Annual General Meeting scheduled for July 15, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_did_Bliss_GVS_Pharma_announce_Q4_FY26_results\"><\/span><strong>When did Bliss GVS Pharma announce Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bliss GVS Pharma&#8217;s board approved audited Q4 FY26 and FY26 financial results on 12 May 2026, with findings filed with BSE and NSE.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Bliss_GVS_Pharmas_business\"><\/span><strong>What is Bliss GVS Pharma&#8217;s business?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bliss GVS Pharma is one of India&#8217;s largest manufacturers of suppositories and pessaries, a specialist pharma company serving global healthcare markets across Africa, Latin America, and Southeast Asia with specialty dosage form medicines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Bliss_GVS_Pharma_Q4_FY26_live_data\"><\/span><strong>Where can I track Bliss GVS Pharma Q4 FY26 live data?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Track Bliss GVS Pharma live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener for real-time data and research on the specialty pharmaceuticals sector.<\/p>\n<p>The <strong>SKF India Industrial Q4 FY26 results<\/strong> performance reflects the company&#8217;s position in its sector.<\/p>\n<p>The <strong>SKF India Industrial Q4 FY26 results<\/strong> performance reflects the company&#8217;s position in its sector.<\/p>\n<p>The <strong>SKF India Industrial Q4 FY26 results<\/strong> performance reflects the company&#8217;s position in its sector.<\/p>\n<p>The <strong>SKF India Industrial Q4 FY26 results<\/strong> performance reflects the company&#8217;s position in its sector.<\/p>\n<p><em>Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE\/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bliss GVS Pharma Q4 FY26 Results: Board Approves FY26 Results Recommends 100 Percent Dividend AGM July 15 2026<\/p>\n","protected":false},"author":26,"featured_media":86517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-86425","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778656674:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["75"],"rank_math_focus_keyword":["Bliss GVS Pharma Q4"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Bliss GVS Pharma Q4 FY26 Results: 100 Percent Dividend FY26 Revenue Rs 868 Crore"],"rank_math_description":["Bliss GVS Pharma Q4 FY26 results: Board approved FY26 audited results on May 12. 100% dividend recommended. FY26 revenue Rs 868 crore, FY26 profit Rs 114 crore. Full analysis."],"_thumbnail_id":["86517"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11180"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/13124712\/Bliss-GVS-Pharma-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/86425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=86425"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/86425\/revisions"}],"predecessor-version":[{"id":86518,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/86425\/revisions\/86518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/86517"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=86425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=86425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=86425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}